CN1189203C - Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer - Google Patents
Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer Download PDFInfo
- Publication number
- CN1189203C CN1189203C CNB021446849A CN02144684A CN1189203C CN 1189203 C CN1189203 C CN 1189203C CN B021446849 A CNB021446849 A CN B021446849A CN 02144684 A CN02144684 A CN 02144684A CN 1189203 C CN1189203 C CN 1189203C
- Authority
- CN
- China
- Prior art keywords
- cream
- hepatitis
- treatment
- chinese medicine
- compound recipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 27
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 24
- 201000007270 liver cancer Diseases 0.000 title abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 24
- 241000222355 Trametes versicolor Species 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000006071 cream Substances 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 229960004793 sucrose Drugs 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 9
- 206010019755 Hepatitis chronic active Diseases 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 238000005728 strengthening Methods 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 7
- 235000014075 Juglans mandschurica Nutrition 0.000 abstract 4
- 244000264601 Juglans mandschurica Species 0.000 abstract 4
- 240000007371 Cuscuta campestris Species 0.000 abstract 2
- 241000123725 Sophora tonkinensis Species 0.000 abstract 2
- 239000011505 plaster Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000002045 lasting effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000594182 Sarcophaga sigma Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019635 Hepatic artery embolism Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229950010911 orazamide Drugs 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- -1 potenxin Chemical compound 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a traditional Chinese medicine for treating liver cirrhosis, hepatitis and liver cancer, which is prepared from main materials, subsidiary materials and auxiliary materials, and can be a granule or a mixture. The present invention is characterized in that the main material is coriolus versicolor P.E., the auxiliary material is compound juglans mandshurica maxim plaster. The compatibility of the medicine comprises: 1 to 4g of coriolus versicolor P.E. and 1.2 to5g of compound juglans mandshurica maxim plaster. The present invention uses rainbow conk as main materials and uses dodder, vietnamese sophora root and manchurian walnut bark as auxiliary materials. The rainbow conk and the dodder which have the effects of strengthening the spleen and nourishing the liver are compounded with the vietnamese sophora root and the manchurian walnut bark which have the effects of clearing heat and removing stasis, and thus, the present invention strengthens body resistance without remaining evils and eliminates evils without hurting body resistance, and the present invention can perform the effect of comprehensively regulating organic internal environment. The present invention has the advantages of reasonable prescription and scientific compatibility and has good therapeutic effects on chronic active hepatitis, continuous positive low concentration AFP and primary liver cancer in period I and period II belonging to the syndrome of damp-heat accumulation.
Description
(1) technical field
The present invention relates to a kind of Chinese patent medicine and production method thereof, specifically relate to a kind of Chinese medicine and production method thereof of the treatment hepatopathy made from Coriolus Versicolor P.E., compound recipe Cortex Juglandis mandshuricae cream.
(2) background technology
Viral hepatitis is a kind of commonly encountered diseases, is the disease of serious danger side of body people ' s health.At China's hepatitis B sickness rate is 24,68/,100,000 populations.About 110,000 people of the annual morbidity of primary hepatocarcinoma, mortality rate is higher, shows that according to the data in Fusui, Qidong, Jiangsu the PLC mortality rate is up to more than 40,/10 ten thousand people.Chronic hepatitis B and primary hepatocarcinoma have substantial connection, have data to show that chronic hepatitis generation hepatocarcinoma person is high 10.76 times than matched group.Alpha-fetoprotein (AFP) low concentration lasting masculin person belongs to the high risk group that hepatocarcinoma takes place, as can be up to 10.3-44.0% without the incidence rate of treatment one hepatocarcinoma in year.At present, the Western medicine of treatment chronic hepatitis has interferon, vidarabine, acycloguanosine etc. at anti-virus aspect; Immunomodulator has prednisone, potenxin, colchicine etc.; Immunopotentiating agent has ribonucleic acid, thymosin, polyporusum bellatus etc.; The medicine that improves hepatocyte function has multivitamin, fructose, Aicamin etc.; The Chinese medicine finished product has silybin, hepatitis spirit, liver-protecting tablet etc.Primary hepatocarcinoma removes operation, hepatic artery embolism, and outside the Therapeutic Method such as anhydrous alcohol injection, radiotherapy, chemotherapy has 5-Fu, Ah's toxin, silk row toxin etc.; Immunization therapy has α and IFN-, natural and weight group IL-2, TNF etc., and Chinese medicine preparation that curative effect is comparatively sure or patent medicine are still few.The report of treatment by Chinese herbs alpha-fetoprotein low concentration lasting masculin then still less.In view of above-mentioned several hepatic disease, mostly based on the treatment of western modern medicine method, toxic and side effects and untoward reaction are bigger.Its curative effect of the Chinese medicine preparation that has come out remains further to verify and determine.
(3) summary of the invention
The technical problem to be solved in the present invention provides a kind of have strengthening the body resistance, heat clearing and damp drying, detoxicating and resolving stagnation of pathogens, and control liver cirrhosis, hepatitis, hepatocarcinoma are had treatment liver cirrhosis, the hepatitis of good efficacy, the Chinese medicine and the production method thereof of hepatocarcinoma.
The technical scheme that adopts is:
A kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma is to be mixed with by 1-4g Coriolus Versicolor P.E., 1.2-5g compound recipe Cortex Juglandis mandshuricae cream; The production method of Coriolus Versicolor P.E. is the high-quality Coriolous Dersicolor (Fr.) Quel that will choose, and amount is put into the water that extraction pot adds 8-10 times of crude drug amount on demand, soaks 8-10 hour, decoct to boiling, steam pressure is no more than 0.13Mpa, and the intrinsic pressure 0.05Mpa that is no more than is keeping little boiling to extract 3 times down; Extracted 3 hours respectively 4 hours; Above-mentioned three extracting solution are merged, left standstill 12-24 hour, get supernatant, put into concentration pan and concentrate receipts cream, operating pressure is less than 0.1MPa, and surveying density down at 20-30 ℃ is 1.08-1.11; 40-45 ℃ the time, adding the concentration that 3-5 doubly measures is the ethanol of 80-95 degree with the extractum that makes, and transferring alcohol back concentration of alcohol is the 60-70 degree, by the centrifuge centrifuge dehydration, after the drying, is Coriolus Versicolor P.E. more then; The production method of compound recipe Cortex Juglandis mandshuricae cream is: get Cortex Juglandis mandshuricae 36.4kg, the Radix Sophorae Tonkinensis 30kg, the Semen Cuscutae 29.96kg that are cut into segment, and put into the extraction pot water and wash, the water that adds 10 times of crude drug amounts, soaked 10 hours, decoct to boiling, steam pressure is no more than 0.13MPa, the intrinsic pressure 0.05MPa that is no more than, boil down keeping little, extract 3 times; 4 hours, 2 hours, sucking filtration with the filtrate merging of above-mentioned three extractions, left standstill respectively, gets supernatant, concentrates and receives cream, and recording density under 30 ℃ of temperature is 1.08-1.11, is compound recipe Cortex Juglandis mandshuricae cream finished product.
Above-mentioned a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma is to be mixed with by Coriolus Versicolor P.E. 1.43g and compound recipe Cortex Juglandis mandshuricae cream 2g.
Above-mentioned a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma during for granule, adds sucrose 51.8-208.8g, dextrin 2.88-11.6g.
Above-mentioned a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma when this medicine is mixture, adds ethanol, and addition is the 54-90% of compound recipe Cortex Juglandis mandshuricae cream amount.
Above-mentioned a kind of production method for the treatment of the Chinese medicine granules of liver cirrhosis, hepatitis, hepatocarcinoma is to get Coriolus Versicolor P.E. 1-4g by charge ratio, cane sugar powder 51.8-208.8g earlier, dextrin 2.88-11.6g joins in the mixer, and start was stirred 10-15 minute, fully mix homogeneously, get compound recipe Cortex Juglandis mandshuricae cream 1.2-5g by charge ratio again, after being the ethanol dilution of 80-95 degree with concentration, add in the mixer, mix, cross 14 mesh sieves, after screening out thick slag, screen out fine powder, be finished product after 80 mesh sieves.
Last a kind of production method for the treatment of the herb mixture of liver cirrhosis, hepatitis, hepatocarcinoma, be to get 1.2-5g compound recipe Cortex Juglandis mandshuricae cream, adding concentration is the ethanol of 80-95 degree, adding amount of alcohol is the 54-90% of compound recipe Cortex Juglandis mandshuricae cream amount, soaks to leave standstill 12-48 hour, filters, filtrate is evaporated to the clear paste that relative density is 1.20-1.30 in the time of 20 ℃, add Coriolus Versicolor P.E. 1-4g again, add the suitable quantity of water dissolving, and adjust to the 72-280 milliliter.
A kind of usage and dosage for the treatment of the Chinese medicine of liver cirrhosis, hepatitis, hepatocarcinoma of the present invention:
1, granule: every packed 10g.
Usage and dosage: oral, a 10g, 3 times on the one, taking medicine after meal.
Function cures mainly: have the effect that alpha-fetoprotein raises that suppresses.Be used for hepatitis, liver cirrhosis, hepatocarcinoma.
2, mixture: whenever bottled (1) 10ml; (2) 100ml.
Usage and dosage: oral.A 10ml, 3 times on the one.Be 4 weeks the course of treatment, 2 courses of treatment of logotype.
Function cures mainly: heat clearing and damp drying, analgesic consolidating.The chronic hepatitis that is used for syndrome of accumulated dampness-heat, alpha-fetoprotein lasting masculin patient, and can be used for the auxiliary treatment of syndrome of accumulated dampness-heat liver cancer patient chemotherapy.
The side separates:
1, the Coriolus Versicolor P.E. main active substances is a krestin, and energy human body immunity improving power presses down tumor, protects the liver.
2, Semen Cuscutae: wherein Quercetin in the composition etc. can activate immunocompetences such as T lymphocyte and macrophage.
3, Radix Sophorae Tonkinensis: its main composition matrine, oxymatrine can resist the system tumor growth, suppress the collagen mobility, protect the liver.
4, Cortex Juglandis mandshuricae: its main composition anthraquinone analog compound energy cancer inhibitting and killing cell, the gi system cancerous cell all there is lethal effect, the 5-Fu that its strength ratio U.S. Sigma company produces is high 5 times, and normal cell is shielded.
A kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma of the present invention is based on Coriolous Dersicolor (Fr.) Quel, and Semen Cuscutae, Radix Sophorae Tonkinensis, Cortex Juglandis mandshuricae are auxilliary.Coriolous Dersicolor (Fr.) Quel, Semen Cuscutae spleen invigorating nourishing the liver; Radix Sophorae Tonkinensis, Cortex Juglandis mandshuricae heat clearing away eliminating stagnation, fit applications are then set upright and do not stayed heresy, and be eliminating evil and just do not hinder, and can play comprehensive Accommodation to organismic internal environment.
Reasonable recipe of the present invention, the compatibility science.
The evidence of animal pharmacodynamics:
To mice S
180Tumor-inhibiting action: tumour inhibiting rate 40-60%
[8]
Tumor-inhibiting action to rat liver cancer: tumour inhibiting rate 33.6-72.4% has significant inhibitory effect to rat liver cancer
[8]
To carboplatin toxicity and anticancer research: chemotherapeutics is had tangible Attenuation, and have stronger active anticancer
[7]
Pass through S
180The cellular immune function experiment of tumor-bearing mice confirms that this medicine can strengthen the cellular immune function of tumor-bearing mice
[8]
Cause the rat blood serum transaminase experiment that raises by carbon tetrachloride, confirm that this medical instrument has tangible alt-reducing and liver-protecting effect
[8]
External five kinds of cancerous cell are suppressed experiment: each quasi-cancer cell is had obvious inhibitory action, and the 5-Fu that its strength ratio U.S. Sigma company produces is high 5 times, and normal cell is shielded
[9]
Its function is strengthening the body resistance, heat clearing and damp drying, detoxicating and resolving stagnation of pathogens, is used for chronic active hepatitis, AFP low concentration lasting masculin, I, II phase primary hepatocarcinoma and belongs to damp-heat accumulation pattern of syndrome person.Its clinical research in early stage promptly proves: this medicine is evident in efficacy to AFP low concentration lasting masculin, Dandong group is observed 55 examples, total effective rate is 92.33%, Haimen group 68 examples, total effective rate is 85.29%, and 1 routine hepatocarcinoma only appears in the treatment group, and 6 examples then appear in matched group, the difference highly significant, its curative effect is appraised through discussion the back by domestic expert twice and is affirmed.In the recent period through the hospital for infectious diseases, Dandong City to chronic active hepatitis 60 routine clinical verifications, total effective rate is 95%; The clinical verification AFP of Nantong City tumour hospital low concentration lasting masculin 90 examples, short term effect is 64.40%, late result is 81.36%; Primary hepatocarcinoma 32 examples, 30 examples, 30 examples are respectively observed by Nantong City tumour hospital, Dandong City institute of traditional Chinese medicine, and the effective percentage of its cancer curative effect is respectively 34.78%, 40.00%, 36.67%, the further checking of having got back of its curative effect.
A kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma of the present invention also through national clinical base cooperative groups such as Beijing China-Japan Friendship Hospital, according to national new drug clinical verification rule, carries out the multi-faceted clinical research of multicenter, and the result is as follows:
One, treatment alpha-fetoprotein low concentration lasting masculin observation of curative effect
Case is selected: low positive patient's 80 examples, male 60 examples, women 20 examples of holding of AFP.
Be divided into treatment at random and organize 50 examples, matched group 30 examples.Age, sex reach and are in hospital and out-patient's distribution processing by statistics there was no significant difference between two groups.
Therapeutic Method: treatment group: mixture, 1 (10ml)/time, 3 times/day, oral 4
Zhou Weiyi course of treatment, omnidistance 2 months.
Matched group: hepatopathy Chinese patent medicine and hepatoprotective.4 weeks were a course of treatment, omnidistance 2 months.
Observed result: 50 examples are organized in treatment all makes the AFP value descend in various degree, and matched group is invalid substantially.See attached list 1, subordinate list 2.
The synopsis of subordinate list 1 treatment alpha-fetoprotein rising assay:
| Group | The example number | Rise (%) | Descend | ||
| ＜1/2(％) | ＞1/2(％) | Normally (%) | |||
| The treatment group | 50 | 0 | 4(8.0) | 24(48.0) | 22(44.0) |
| Matched group | 30 | 16(53.3) | 14(46.6) | 0 | 0 |
Two groups of 1/2 above persons that descend there were significant differences P＜0.01
Therapeutic effect of syndrome synopsis before and after subordinate list 2 treatments
| Symptom | Treatment group (50 example) | Matched group (30 example) | ||||
| Before the treatment | Significant figure | Effective percentage % | Before the treatment | Significant figure | Effective percentage % | |
| *The both sides of the chest distending pain | 23 | 16 | 69.6 | 8 | 5 | 62.5 |
| **The vexed abdominal distention of gastral cavity | 15 | 12 | 80.0 | 9 | 4 | 44.4 |
| **Heating installation is indigestion and loss of appetite | 16 | 10 | 62.5 | 10 | 4 | 40.0 |
| **Bitter taste in the mouth and dry throat | 33 | 24 | 72.7 | 17 | 9 | 52.9 |
| *Weak | 28 | 18 | 64.3 | 13 | 7 | 53.8 |
Two groups are relatively:
*P＞0.05
*Improve P＜0.01 i.e. two groups of syndromes, has three to have significant difference.
Hepatocarcinoma 20 examples in the treatment group, the back AFP that takes medicine all has decline in various degree.10 routine decline numerical value (＞1/2) over half wherein, 6 examples reach normally.6 examples reach normal person 4 routine long-term survivings, 2 example survivals 2 years.20 routine chronic active hepatitiss in other 30 examples, 10 routine liver cirrhosis.The AFP soprano reaches 1850ng/ml, takes mixture 2 months, and AFP reduces to normally.Be interrupted later on and took medicine 2 years, normal all the time, existing energy operate as normal.26 examples are through following the trail of more than 1 year none routine canceration in 30 examples.
10 routine hepatocarcinoma are all dead in 1 year in the matched group.20 routine chronic active hepatitis patient AFP test rating fluctuations have 5 routine cancerations low-level.
Discuss: 1, observe confirming through clinical control, Chinese medicine of the present invention truly has obvious curative effects to the AFP rising of control chronic active hepatitis, liver cirrhosis, liver cancer patient, has no adverse reaction.
2, some liver cancer patient is taken this product and is cooperated other anti-cancer therapies, can be than the matched group long term survival.
3, through 1-2 tracing study AFP once rising person, have up to more than the 1000ng/ml, the fact of none routine canceration, prove the present invention have control canceration effect.
Two, treatment primary hepatocarcinoma clinical verification report
Case is selected: this group hepatocarcinoma case 120 examples are all worn biopsy through clinical, B ultrasonic, CT, liver and are diagnosed as primary hepatocarcinoma.Estimate life cycle more than two months, the inpatient that physical situation is fair adopts random method to be divided into two groups, and packet conditions is by statistical procedures, there was no significant difference.60 examples are organized in treatment, matched group 60 examples.
Therapeutic Method: treatment group: mixture 10ml/ props up, and 3 times/day, each one.Viewing duration is not taken Chinese medicine and Chinese medicine preparation.
Main therapy is local puncture injection anhydrous alcohol of the swollen thing of hepatocarcinoma and an interleukin II therapy under the B ultrasonic guiding.1-2 time weekly.
Matched group: do not take Chinese medicine of the present invention, main therapy is the same, the anti-hepatocarcinoma immune ribonucleic acid of this group patient while intramuscular injection 4mg, the next day once.
Observed result: see attached list 3.
The objective efficacy evaluation of subordinate list 3 cancer
| Group | The example number | CR | PR | SD | PD | Effective percentage (%) |
| The treatment group | 60 | 2 | 20 | 26 | 12 | 36.67 |
| Matched group | 60 | 2 | 12 | 20 | 26 | 23.33 |
Effective percentage=CR+PR Ridit: u=1.678 P＞0.05
A kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma of the present invention, through the long-term toxicity test for animals that Shenyang Pharmacy College, institute of Chinese materia medica, Dandong, Chinese Medical Sciences University's the 3rd hospital pathology department carry out, conclusion is: the observation of carrying out the long period under the effect of big dose does not find that medicine causes poison to pay effect to liver, renal function and the routine blood test of the animal that is put to the test.
(4) specific embodiment
A kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma is to be mixed with by Coriolus Versicolor P.E. 1.43g and compound recipe Cortex Juglandis mandshuricae cream 2g.
The adjuvant that adds when one, making granule is sucrose, dextrin, its charge ratio is Coriolus Versicolor P.E. 14.3kg, compound recipe Cortex Juglandis mandshuricae cream 20kg, cane sugar powder 72kg, dextrin 4kg, add above-mentioned Coriolus Versicolor P.E., cane sugar powder, dextrin in the mixer successively, start was stirred 10-15 minute, fully mix homogeneously; After above-mentioned Cortex Juglandis mandshuricae cream being added 90 ° of ethanol 20kg dilutions again, add in the mixer,, granulate through wet mixing pelletizer with the above-mentioned raw materials mix homogeneously; cross 14 mesh sieves and make granule, granule is crossed 14 mesh sieves earlier behind boiled bed drying; screen out thick slag, screen out fine powder, be finished product after 80 mesh sieves.Be distributed into bag through racking machine, theoretical yield is 100,000 bags.
When two, making mixture, the adjuvant of adding is an ethanol.Its preparation method is:
1, get Coriolus Versicolor P.E. 143kg, 400kg is standby for compound recipe Cortex Juglandis mandshuricae cream.
2,400kg compound recipe Cortex Juglandis mandshuricae cream being added 280kg concentration is 90 ° ethanol, left standstill 24 hours, filter, filtrate is evaporated to the clear paste that relative density is 1.20-1.30 (20 ℃) with the combination type concentration pan, add the 143kg Coriolus Versicolor P.E., add the suitable quantity of water dissolving, make it to adjust volume to 10000ml, and dress up bottle with filling machine, theoretical amount is 1000 bottles.
Three, the manufacture method of Coriolus Versicolor P.E.
Get the selected high-quality Coriolous Dersicolor (Fr.) Quel of 100kg, put into extraction pot, add the water of 10 times of amounts of crude drug, soaked 8 hours, decoct to boiling, steam pressure is no more than 0.13MPa, the intrinsic pressure 0.05MPa that is no more than.Keeping under little condition of boiling, extract three times, be respectively and extracted 4 hours, 3 hours, 3 hours, difference sucking filtration during extraction, filtrate with three extractions merges again, leaves standstill, and gets supernatant and puts into the concentrated cream of receiving of ZWN-1000 type combination type concentration pan, operating pressure is no more than 0.1MPa, and recording extractum density under 20 ℃ of temperature is 1.08-1.11.Under 45 ℃, the concentration that adds 5 times of amounts is 85 ° ethanol with the extractum produced, and transferring alcohol back concentration of alcohol is the 60-70 degree, the centrifuge dehydration of reuse SS-800 type centrifuge, and centrifugation time 15 minutes after drying under the 50-80 ℃ of temperature, is the Coriolus Versicolor P.E. finished product.
Four, the manufacture method of compound recipe Cortex Juglandis mandshuricae cream
1, with 100kg Cortex Juglandis mandshuricae 100kg Radix Sophorae Tonkinensis, remove impurity respectively, usefulness cuts the formula medicine cutter or the JQ guillotine is cut into the section of 10cm, the section of 6-8cm respectively.
2, with Semen Cuscutae flush away silt.
3, get Cortex Juglandis mandshuricae 36.4kg, Radix Sophorae Tonkinensis 30kg, Semen Cuscutae 29.96kg puts into extraction pot, add 10 times of water gagings, soaked 10 hours, decoct to boiling, steam pressure is no more than 0.13MPa, the intrinsic pressure 0.05MPa that is no more than, keeping under little situation of boiling, extract 3 times with the multi-functional extraction unit of 3T type, be respectively 4 hours, 2 hours, 2 hours, and the difference sucking filtration, and with three extracting solution merging, put into ZWN-1000 type combination type concentration pan concentrated medicament, receiving cream density is 1.08-1.11 (at 30 ℃ of density measurements), is compound recipe Cortex Juglandis mandshuricae cream finished product.
Claims (6)
1, a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma is characterized in that being mixed with by 1-4g Coriolus Versicolor P.E., 1.2-5g compound recipe Cortex Juglandis mandshuricae cream; The production method of Coriolus Versicolor P.E. is: with the high-quality Coriolous Dersicolor (Fr.) Quel of choosing, amount is put into extraction pot on demand, adds the water of 8-10 times of crude drug amount, soaked 8-10 hour, and decocted to boiling, steam pressure is no more than 0.13MPa, the intrinsic pressure 0.05MPa that is no more than boils down keeping little, extracts 3 times; Extracted respectively 4 hours, 3 hours, 3 hours; Above-mentioned three extracting solution are merged, left standstill 12-24 hour, get supernatant, put into concentration pan and concentrate receipts cream, operating pressure is less than 0.1MPa, and surveying density down at 20-30 ℃ is 1.08-1.11; 40-45 ℃ the time, adding the concentration that 3-5 doubly measures is the ethanol of 80-95 degree with the extractum that makes, and transferring alcohol back concentration of alcohol is the 60-70 degree, by the centrifuge centrifuge dehydration, after the drying, is Coriolus Versicolor P.E. more then; The production method of compound recipe Cortex Juglandis mandshuricae cream is: get Cortex Juglandis mandshuricae 36.4kg, the Radix Sophorae Tonkinensis 30kg, the Semen Cuscutae 29.96kg that are cut into segment, and put into the extraction pot water and wash, the water that adds 10 times of crude drug amounts, soaked 10 hours, decoct to boiling, steam pressure is no more than 0.13MPa, the intrinsic pressure 0.05MPa that is no more than, boil down keeping little, extract 3 times; 4 hours, 2 hours, 2 hours, sucking filtration with the filtrate merging of above-mentioned three extractions, left standstill respectively, gets supernatant, concentrates and receives cream, and recording density under 30 ℃ of temperature is 1.08-1.11, is compound recipe Cortex Juglandis mandshuricae cream finished product.
2, a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma according to claim 1 is characterized in that being mixed with by Coriolus Versicolor P.E. 1.43g and compound recipe Cortex Juglandis mandshuricae cream 2g.
3, a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma according to claim 1 when it is characterized in that this medicine is granule, adds sucrose 51.8-208.8g, dextrin 2.88-11.6g.
4, a kind of Chinese medicine for the treatment of liver cirrhosis, hepatitis, hepatocarcinoma according to claim 1 when it is characterized in that this medicine is mixture, adds ethanol, and addition is the 54-90% of compound recipe Cortex Juglandis mandshuricae cream amount.
5, a kind of production method for the treatment of the Chinese medicine granules of liver cirrhosis, hepatitis, hepatocarcinoma according to claim 3, it is characterized in that getting Coriolus Versicolor P.E. 1-4g by charge ratio earlier, cane sugar powder 51.8-208.8g, dextrin 2.88-11.6g joins in the mixer, start was stirred 10-15 minute, abundant mix homogeneously, get compound recipe Cortex Juglandis mandshuricae cream 1.2-5g by charge ratio again, after being the ethanol dilution of 80-95 degree with concentration, add in the mixer, mix, cross 14 mesh sieves, after screening out thick slag, screen out fine powder, be finished product after 80 mesh sieves.
6, a kind of production method for the treatment of the herb mixture of liver cirrhosis, hepatitis, hepatocarcinoma according to claim 4, it is characterized in that getting 1.2-5g compound recipe Cortex Juglandis mandshuricae cream, adding concentration is the ethanol of 80-95 degree, adding amount of alcohol is the 54-90% of compound recipe Cortex Juglandis mandshuricae cream amount, soaks to leave standstill 12-48 hour, filters, filtrate is evaporated to the clear paste that relative density is 1.20-1.30 in the time of 20 ℃, add Coriolus Versicolor P.E. 1-4g again, add the suitable quantity of water dissolving, and adjust to the 72-280 milliliter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021446849A CN1189203C (en) | 2002-12-05 | 2002-12-05 | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021446849A CN1189203C (en) | 2002-12-05 | 2002-12-05 | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1421229A CN1421229A (en) | 2003-06-04 |
| CN1189203C true CN1189203C (en) | 2005-02-16 |
Family
ID=4750634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021446849A Expired - Lifetime CN1189203C (en) | 2002-12-05 | 2002-12-05 | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1189203C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843657A (en) * | 2010-02-10 | 2010-09-29 | 李瑞菊 | Medicinal composition |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100335070C (en) * | 2005-10-14 | 2007-09-05 | 中国药科大学 | Coriolus versicolor zymolyte, its preparation method and use for adjuvant as alcoholic drink |
| CN100340252C (en) * | 2006-07-04 | 2007-10-03 | 刘海刚 | Synergistic medicinal composition containing thiopronin and Chinese medicine extract |
| CN100367980C (en) * | 2006-08-17 | 2008-02-13 | 陈乃车 | Cooperative compositions comprising biphenyldicarboxylate |
| CN104286859B (en) * | 2014-10-23 | 2016-03-30 | 广东岭南职业技术学院 | A kind of for health food improving chemical damage and preparation method thereof |
| CN107037146B (en) * | 2017-02-17 | 2020-12-15 | 丹东药业集团有限公司 | Method for controlling quality of compound wood chicken granules |
| CN107982383A (en) * | 2018-01-25 | 2018-05-04 | 辽东学院 | A kind of Chinese medicine composition for treating liver cancer and its preparation method and application |
| CN110548123A (en) * | 2019-09-21 | 2019-12-10 | 王冶 | A Chinese medicinal composition for adjuvant treatment of liver cirrhosis and hepatocarcinoma, and its preparation method |
-
2002
- 2002-12-05 CN CNB021446849A patent/CN1189203C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843657A (en) * | 2010-02-10 | 2010-09-29 | 李瑞菊 | Medicinal composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1421229A (en) | 2003-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1189203C (en) | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN101773532B (en) | Carpesium abrotanoides total terpene lactones extract | |
| CN1298362C (en) | Compound Chinese medicine prepn for treating pulvic infection and its prepn process | |
| CN1857684A (en) | Compound Chinese medicine preparation for removing toxic matter, dispersing blood clots and strengthing body's resistance and its preparaing process | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN1927315A (en) | Medicine for treating psoriasis mainly and its preparation method and use | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN101357212B (en) | Compound cantharis injection and preparation method thereof | |
| CN1264547C (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1879755A (en) | Chinese medicinal composition for preparing tumor-treating medicine | |
| CN103239674A (en) | Antineoplastic traditional Chinese medicine composition and preparation method thereof | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1053381C (en) | Drug for promoting puerperal physiological recovery and curing postpartum disease | |
| CN1834108B (en) | Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition | |
| CN1823884A (en) | Preparation method of aidi injection agent | |
| CN101062108A (en) | Medicinal composition for treating dysmenorrhea and preparation process thereof | |
| CN1883654A (en) | Pulse invigorating injection with astragalus root and preparation process thereof | |
| CN1927366A (en) | Traditional Chinese medicine composition for treating chronic enterogastritis | |
| CN1258373C (en) | Medicine for treating lumbosacral pain and its preparing method | |
| CN104840746B (en) | A kind of Chinese medicine composition with anti-lung cancer activity and its preparation method and application | |
| CN101502635B (en) | Medicament composition containing Reserpine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: No. 10, health Road, Zhenxing District, Liaoning, Dandong Patentee after: DANDONG PHARMACEUTICAL GROUP CO.,LTD. Address before: No. 10 Da Ling Road, Zhenxing District, Liaoning, Dandong Patentee before: Dandong Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: DANDONG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: DANDONG PHARMACEUTICALS CO., LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050216 |
|
| CX01 | Expiry of patent term |